Ohad Hammer

Poniard Pharmaceuticals: Platinum Rediscovered (Part II)

Thanks.
The EXEL piece will be published next week end. They must wait to GSK's decision in order to monetize their portoflio, but I expect several deals already this year.

Ohad

Poniard Pharmaceuticals: Platinum Rediscovered (Part II)

Indeed, I am very bullish on EXEL. I don't have any writeups on them, maybe later this year, if I have the time.
EXEL has so many shots on goal, with an excellent strategy of focusing on niche markets first, so the risk/reward ratio is quite compelling.